Neratinib

Neratinib
Clinical data
Trade names	Nerlynx, Hernix
Other names	HKI-272
AHFS/Drugs.com	Monograph
MedlinePlus	a617034
License data	EU EMA: by INN; US DailyMed: Neratinib; US FDA: Nerlynx;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
Drug class	Antineoplastic agent
ATC code	L01EH02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (2E)-N-[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;
CAS Number	698387-09-6 ;
PubChem CID	9915743;
IUPHAR/BPS	5686;
DrugBank	DB11828 ;
ChemSpider	8091392 ;
UNII	JJH94R3PWB;
KEGG	D08950 ; as salt: D10898 ;
ChEMBL	ChEMBL180022 ;
CompTox Dashboard (EPA)	DTXSID70220132 ;
ECHA InfoCard	100.241.512
Chemical and physical data
Formula	C30H29ClN6O3
Molar mass	557.05 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C;
	InChI InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+ ; Key:JWNPDZNEKVCWMY-VQHVLOKHSA-N ;
	(what is this?) (verify)

Neratinib (INN), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer.

The most common side effect is diarrhea, which affects nearly all patients. Other common side effects include nausea (feeling sick), vomiting, tiredness, belly pain, rash, decreased appetite, stomatitis (sore, inflamed mouth), and muscle spasms.